Interleukin-1 receptor antagonist transiently impairs antibacterial defense but not survival in murine pneumococcal pneumonia

European Cytokine Network

Volumn 14, Issue 4, 2003, Pages 242-245

  Rijneveld, Anita W ^a,b   Florquin, Sandrine ^a,b   Speelman, Peter ^a,b,c   Edwards, Carl K ^a,d   Dinarello, Charles A ^a,e   Van Der Poll, Tom ^a,b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Dept of Exp Internal Medicine ^*  (United States)

^c Dept Infect Dis Trop Med AIDS   (United States)

^d AMGEN INC   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Cytokines; Interleukin 1 receptor antagonist; Mouse; Pneumonia; S. Pneumoniae

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HOST RESISTANCE; IMMUNE RESPONSE; LOBAR PNEUMONIA; MOUSE; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; IMMUNE SYSTEM; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LUNG; MICE; PNEUMONIA, PNEUMOCOCCAL; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TIME FACTORS;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 1642498343     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dinarello CA. 2000. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343: 732.
2. Bresnihan B. 2001. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin. Arthritis. Rheum. 30: 17.
3. Bresnihan B. 2001. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Bio-Drugs 15: 87.
4. Gabay C, Arend WP. 1998. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin. Immunopathol. 20: 229.
5. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D. 2000. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43: 1001.
6. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337: 1029.
7. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340: 253.
8. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594.
9. Maini RE, St Clair W, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Attract Study Group. Lancet 354: 1932.
10. Feldmann M, Maini RN. 2001. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163.
11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357: 1842.
12. Gorman JD, Sack KE, Davis JC. 2002. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346: 1349.
13. Chen W, Havell EA, Moldawer LL, McIntyre KW, Chizzonite RA, Harmsen AG. 1992. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii. Journal of Experimental Medicine 176: 713.
14. Kozak W, Zheng H, Conn CA, Soszynski D, van der Ploeg LH, J. Kluger M. 1995. Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1 beta-deficient mice. American Journal of Physiology 269: R969.
15. Rijneveld AW, Florquin S, Branger J, Speelman P, Van Deventer SJ, van der Poll T. 2001. TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J. Immunol. 167: 5240.
16. van der Poll T, Keogh CV, Buurman WA, Lowry SF. 1997. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. American Journal of Respiratory, Critical Care Medicine 155: 603.
17. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345: 1098.
18. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford). 2003 May; 42 Suppl 2: ii 29-35.
19. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis. 31: 347.
20. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191: 313.
21. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. 2000. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 191: 303.
22. Bendele A, McAbee T, Woodward M, Scherrer J, Collins D, Frazier J, Chlipala E, McCabe D. 1998. Effects of interleukin-1 receptor antagonist in a slow-release hylan vehicle on rat type II collagen arthritis. Pharm. Res. 15: 1557.
23. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, Edwards CK, 3rd 2000. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PE-Gylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 43: 2648.
24. Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater JC, van Rooijen N, van der Poll T. 2002. Alveolar Marophages have a rotective Anti-inflammatory Role during Murine Pneumococcal Pneumonia. Am. J. Respir. Crit. Care Med. in press.
25. Verreck FA, de Boer T, Hoeve M, van Dissel JT, Sanal O, Kurimoto M, Ottenhoff TH. 2002. Human host defense and cytokines in mycobacterial infectious diseases: interleukin-18 cannot compensate for genetic defects in the interleukin-12 system. Clin. Infect. Dis. 35: 210.